Esperion Therapeutics, Inc. (ESPR) financial statements (2021 and earlier)

Company profile

Business Address 3891 RANCHERO DRIVE, SUITE 150
ANN ARBOR, MI 48108
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments305201136200212212106
Cash and cash equivalents3051663734387785
Short-term investments 359916617313521
Inventory, net of allowances, customer advances and progress billings16      
Inventory16      
Other undisclosed current assets251174221
Total current assets:346212143204214214107
Noncurrent Assets
Operating lease, right-of-use asset62
Property, plant and equipment1110111
Long-term investments and receivables  073318036
Long-term investments  073318036
Intangible assets, net (including goodwill)0000000
Intangible assets, net (excluding goodwill)0000000
Total noncurrent assets:73174328137
TOTAL ASSETS:353214143278245296143
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities77414822623
Accounts payable52294520512
Accrued liabilities251231111
Employee-related liabilities      0
Deferred revenue22
Debt 0 1221
Other liabilities      0
Other undisclosed current liabilities16231611822
Total current liabilities:946664331665
Noncurrent Liabilities
Long-term debt and lease obligation1831  134
Long-term debt, excluding current maturities179   134
Operating lease, liability31
Liabilities, other than long-term debt1      
Other liabilities1      
Other undisclosed noncurrent liabilities171127     
Total noncurrent liabilities:355128  134
Total liabilities:449194643317810
Stockholders' equity
Stockholders' equity attributable to parent(96)2079245229287134
Common stock0000000
Treasury stock, value(55)      
Additional paid in capital798715678642458442238
Accumulated other comprehensive income (loss) 0(0)(1)(0)(0)(0)
Accumulated deficit(839)(695)(598)(396)(229)(154)(104)
Total stockholders' equity:(96)2079245229287134
TOTAL LIABILITIES AND EQUITY:353214143278245296143

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:228148     
Operating expenses(349)(241)(205)(169)(76)(50)(36)
Operating loss:(121)(93)(205)(169)(76)(50)(36)
Nonoperating income
(Other Nonoperating income)
1432210
Interest and debt expense(23)(8) (0)(0)(1)(0)
Net loss available to common stockholders, diluted:(144)(97)(202)(167)(75)(50)(36)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(144)(97)(202)(167)(75)(50)(36)
Comprehensive loss:(144)(97)(202)(167)(75)(50)(36)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)01(1)0(0)(0)
Comprehensive loss, net of tax, attributable to parent:(144)(97)(201)(168)(75)(50)(36)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: